camptothecin has been researched along with Carcinoma, Anaplastic in 162 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.62) | 18.7374 |
| 1990's | 18 (11.11) | 18.2507 |
| 2000's | 75 (46.30) | 29.6817 |
| 2010's | 64 (39.51) | 24.3611 |
| 2020's | 4 (2.47) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, SB; Gu, LQ; Huang, SL; Huang, ZH; Huang, ZS; Li, D; Ou, JB; Ou, TM; Shen, LL; Tan, JH; Wu, WB | 1 |
| Chiang, RS; Colevas, AD; Shukla, ND | 1 |
| Altwerger, G; Andikyan, V; Azodi, M; Bellone, S; Buza, N; Clark, M; Demirkiran, C; Dottino, PR; Harold, JA; Hartwich, TMP; Huang, GS; Hui, P; Manavella, DD; Mauricio, D; McNamara, B; Mutlu, L; Ratner, ES; Santin, AD; Schwartz, PE; Siegel, ER; Verzosa, MSZ; Yang-Hartwich, Y | 1 |
| Artru, P; Auclin, E; Auvray, M; Coriat, R; Hammel, P; Hautefeuille, V; Lecaille, C; Lecomte, T; Locher, C; Moulin, V; Pernot, S; Sickersen, G; Taieb, J; Tougeron, D; Vernerey, D | 1 |
| Habib, M; Jorns, C; Nilsson, PJ; Nordenvall, C; Sparrelid, E; Villard, C | 1 |
| Guo, H; Han, K; Tang, H; Yan, Y; Zhang, J; Zhang, L; Zhang, X; Zhuang, K | 1 |
| Bilancia, D; Cascinu, S; Corsi, DC; Ferraú, F; Galli, F; Giordano, M; Iaffaioli, RV; Labianca, R; Leone, F; Lonardi, S; Marchetti, P; Nasti, G; Ronzoni, M; Rosati, G; Scartozzi, M; Zagonel, V; Zaniboni, A | 1 |
| Peng, S; Shan, S; Wang, J; Wang, L; Wu, J; Xiao, N; Yu, K; Yu, S; Zheng, S | 1 |
| Amar, Y; Berger, F; Bieche, I; Cacheux, W; Canet, J; Cartier, A; de Koning, L; Guimbaud, R; Guyetant, S; Lecomte, T; Lièvre, A; Mariani, O; Ouine, B; Selves, J | 1 |
| Hosoda, Y; Katsushima, U; Kawai, J; Kiyochi, H; Komoto, I; Nishiyama, K; Ogura, N; Okabe, A; Oshima, Y; Sugimoto, T; Taki, Y; Tsunekawa, S; Yanagihara, K | 1 |
| Kawano, K; Matsukuma, K; Nasu, H; Nishio, S; Shimokawa, M; Tasaki, K; Terada, A; Tsuda, N; Ushijima, K; Yoshimitsu, T | 1 |
| Cincinelli, R; Dallavalle, S; De Santis, R; Giannini, G; Minenkova, O; Musso, L; Santapaola, D; Vesci, L | 1 |
| Han, Y; Li, YH; Liang, JY; Liu, W; Wang, K; Xing, BC | 1 |
| Gajdos, C; Jones, EL; Jones, TS; McManus, M; Shah, R | 1 |
| Carlomagno, C; Cella, CA; De Placido, S; De Stefano, A; Matano, E; Moretto, R; Raimondo, L | 1 |
| Jin, JY; Lee, GJ; Lee, MY; Min, JW; Seo, MW | 1 |
| Elias, D; Eveno, C; Gayat, E; Glehen, O; Goéré, D; Passot, G; Pocard, M; Soyer, P | 1 |
| Liu, B; Shen, J; Wang, J; Wang, L; Xie, L | 1 |
| Bakrin, N; Cotte, E; Gilly, FN; Glehen, O; Passot, G; Roux, AS; Vaudoyer, D | 1 |
| Hiotis, S; Jibara, G; Labow, DM; Romanoff, A; Sarpel, U; Shrager, B; Tabrizian, P; Yang, MJ | 1 |
| Hasegawa, K; Ichikawa, R; Kato, R; Kawamura, K; Oe, S; Torii, Y; Udagawa, Y | 1 |
| Billard, V; Blot, F; Cloutier, AS; Dartigues, P; Ducreux, M; Dumont, F; Elias, D; Goéré, D; Honoré, C; Mariani, A | 1 |
| Cain, J; Drummond, DC; Fitzgerald, JB; Kalra, AV; Kim, J; Klinz, SG; Nielsen, UB; Paz, N | 1 |
| Aksoy, A; Arpaci, E; Bahceci, A; Bayoglu, IV; Besiroglu, M; Dane, F; Duran, AO; Hacibekiroglu, I; Inanc, M; Karaca, H; Menekse, S; Ozkan, M; Sevinc, A; Tanriverdi, O; Uysal, M; Yapici, HS; Yazilitas, D | 1 |
| Christie, M; Desai, J; Diaz, LA; Gibbs, P; Karapetis, CS; Kinde, I; Kinzler, KW; Papadopoulos, N; Roebert, J; Singh, M; Strausberg, RL; Tacey, M; Tie, J; Tran, B; Vogelstein, B; Wang, Y; Wong, HL; Wong, R | 1 |
| Botti, G; Ciardiello, F; Colucci, G; Esposito, C; Fenizia, F; Lambiase, M; Maiello, E; Martinelli, E; Normanno, N; Rachiglio, AM; Rizzi, D; Roma, C; Tatangelo, F; Troiani, T | 1 |
| Bonetti, A; Giuliani, J; Piacentini, P | 1 |
| Barnes, JC; Bruno, PM; Hemann, MT; Johnson, JA; Liao, L; Liu, J; Nguyen, HV | 1 |
| Kimura, T; Kobayashi, E; Kozasa, K; Mabuchi, S; Owa, T; Tomimatsu, T; Tsutui, T; Yamashita, M; Yoki, T; Yokoi, E | 1 |
| Flint, S; Galvin, S; Nestor, LA | 1 |
| Gloor, B; Rau, T; Vinzens, S; Wochner, A; Zindel, J; Zweifel, M | 1 |
| Alvarez Z, M; González D, R; Jarufe C, N; Martínez C, J | 1 |
| Arai, T; Boku, N; Inaba, Y; Komatsu, Y; Mizunuma, N; Nishina, T; Sakata, Y; Satoh, T; Shirao, K; Tahara, M; Takiuchi, H; Yamaguchi, K | 1 |
| Bonastre, J; Brouquet, A; Chevalier, J; Classe, JM; Elias, D; Ferron, G; Goéré, D; Guilloit, JM; Lefevre, JH; Marchal, F; Meeus, P | 1 |
| Ambrosi, A; Calise, S; Costantino, E; Esposito, F; Fersini, A; Landriscina, M; Maddalena, F; Neri, V; Piscazzi, A; Tirino, V | 1 |
| Baracos, VE; Dieleman, LA; Field, CJ; Sawyer, MB; Xue, H | 1 |
| Kocák, I; Kocáková, I; Lakomý, R; Nēmecek, R; Poprach, A; Svoboda, M; Vyskocil, J; Vyzula, R | 1 |
| Chang, YT; Chen, CW; Chu, KS; Lin, SR; Lu, CY; Tsai, HL; Wang, HM; Wang, JY; Yeh, YS; Yen, LC | 1 |
| Ho, YH; Lam, AK; Sebesan, S; Weekes, J | 1 |
| Bordonaro, R; Caputo, G; Cordio, S; Manzione, L; Novello, G; Reggiardo, G; Rosati, G | 1 |
| Jang, SY; Jung, YW; Kim, JH; Kim, JW; Kim, S; Kim, SW; Kim, YT; Lee, DW; Nam, EJ | 1 |
| Chauffert, B; Ghiringhelli, F; Guiu, B; Ladoire, S | 1 |
| Chatelut, E; Ferron, G; Gadiou, M; Gladieff, L; Halilou, MC; Hennebelle, I; Herin, F; Simon, L | 1 |
| Cardillo, TM; Goldenberg, DM; Govindan, SV; Hansen, HJ; Moon, SJ | 1 |
| Feilchenfeldt, J; Power, DG | 1 |
| Aulicino, C; Bargiotti, A; Bucci, F; Castorina, M; Dal Pozzo, A; Dallavalle, S; Esposito, E; Foderà, R; Giannini, G; Musso, L; Ni, MH; Penco, S; Pisano, C; Vesci, L | 1 |
| Chen, GQ; Cheng, JK; Shen, SM; Wang, LS; Wu, YL; Yu, Y | 1 |
| Creemers, GJ; de Jong, FA; Friberg, LE; Loos, WJ; Mathijssen, RH; Planting, AS; Sparreboom, A; van der Bol, JM; Verweij, J; Wiemer, EA | 1 |
| Chung, HH; Kang, S; Kang, SB; Kim, HS; Kim, JW; Park, NH; Seo, SS; Song, YS | 1 |
| Bandres, E; Bitarte, N; Chopitea, A; Gacía-Foncillas, J; Patiño-Garcia, A; Ponz-Sarvise, M; Ramirez, N; Rodríguez, J; Viudez, A; Zarate, R | 1 |
| Drolet, P; Dubé, P; Sideris, L; Turcotte, S; Younan, R | 1 |
| Andrasina, T; Boudný, J; Bower, M; Martin, RC; Metzger, T; Robbins, K; Tatum, C; Tomalty, D; Válek, V | 1 |
| Chang, PL; Feng, TH; Juang, HH; Lin, YF; Tsui, KH | 1 |
| Cho, DH; Hong, YS; Jin, DH; Jung, KA; Kim, JC; Kim, SM; Kim, TW; Lee, JS; Na, YS; Ro, S; Ryu, MH; Yang, SJ | 1 |
| Kaley, K; Saif, MW | 1 |
| Barber, B; Gregory, C; Long, SR; Song, X; Wang, PF; Zhao, Z | 1 |
| Chua, TC; Doerfer, J; Esquivel, J; Germer, CT; Kerscher, AG; Maeder, U; Morris, DL; Pelz, JO; Stojadinovic, A | 1 |
| Aoki, M; Fujii, M; Murata, T; Oda, K | 1 |
| Akutsu, N; Fujii, H; Hamamoto, Y; Miyamoto, J; Nagase, M; Nishi, T; Warita, E; Yamanaka, Y | 1 |
| Frifeldt, SK; Jakobsen, A; Lindebjerg, J; Pallisgaard, N; Spindler, KL | 1 |
| Boot, H; Hompes, D; van Tinteren, H; Verwaal, V | 1 |
| Andreola, F; Campisi, M; Mercuri, L; Moroni, N; Pierimarchi, P; Psaila, R; Renier, D; Secchieri, C; Serafino, A; Zonfrillo, M | 1 |
| Ando, M; Fujiwara, Y; Hirata, T; Katsumata, N; Ono, M; Shimizu, C; Tamura, K; Yamamoto, H; Yonemori, K | 1 |
| Hosomi, Y; Iguchi, M; Okamura, T; Okuma, Y; Shibuya, M; Takagi, Y | 1 |
| Basseville, A; Boisdron-Celle, M; Coqueret, O; de Carné Trécesson, S; Gamelin, E; Morel, A; Preisser, L | 1 |
| Abenhardt, W; Decker, T; Dietzfelbinger, H; Fischer von Weikersthal, L; Giessen, C; Haberl, C; Hass, HG; Heinemann, V; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; Zellmann, K | 1 |
| Bedenne, L; Bonnetain, F; Brixi-Benmansour, H; Cadiot, G; Hentic, O; Jouve, JL; Landi, B; Mitry, E | 1 |
| Bechter, O; Dlaska, M; Eisterer, W; Fridrik, MA; Greil, R; Grünberger, B; Mayrbäurl, B; Obrist, P; Russ, G; Thaler, J; Wöll, E; Zabernigg, A | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Kobayashi, E; Matsuzaki, S; Miyoshi, Y; Morimoto, A; Ueda, Y; Yokoyama, T; Yoshino, K | 1 |
| Chang-Yun, L; Elnemr, A; Hirano, M; Ichinose, M; Ishibashi, H; Kitai, T; Li, Y; Matsuda, N; Mizumoto, A; Ozamto, Y; Sako, S; Takao, N; Togawa, T; Xiao-Jun, Y; Yonemura, Y | 1 |
| Capussotti, L; Ferrero, A; Langella, S; Lo Tesoriere, R; Russolillo, N; Vigano', L | 1 |
| Crea, F; Cremolini, C; Danesi, R; Falcone, A; Fornaro, L; Graziano, F; Loupakis, F; Masi, G; Paolicchi, E; Ricci, V; Ronzoni, M; Salvatore, L; Schirripa, M | 1 |
| Andersson, R; Norman, P; Spelt, L; Tingstedt, B; Törnqvist, L | 1 |
| Blazer, DG; Hsu, D; Papalezova, K; Stinnett, S; Tyler, D; Zani, S | 1 |
| Cervinka, M; John, S; Rudolf, E | 1 |
| Deng, L; He, J; Huang, Y; Yi, C; Yu, S; Zhao, F; Zhu, H | 1 |
| Bartek, J; Bartkova, J; Bouchal, J; Korinkova, G; Lau, A; Lenobel, R; Lukas, J; Mistrik, M; O'Connor, MJ; Oplustilova, L; Simkova, D; Wolanin, K | 1 |
| Hashimoto, T; Hotta, T; Iwamoto, H; Matsuda, K; Oku, Y; Takifuji, K; Yamaue, H; Yokoyama, S | 1 |
| Berger, A; Brieau, B; Dubreuil, O; Landi, B; Lepère, C; Markoutsaki, T; Rougier, P; Roussel, H; Taieb, J; Trouilloud, I; Vaillant, JN; Zaanan, A | 1 |
| Bozko, P; Larsen, AK; Raymond, E; Skladanowski, A | 1 |
| Boltze, C; Halangk, W; Hribaschek, A; Krüger, S; Kuhn, R; Lippert, H; Pross, M; Ridwelski, K | 1 |
| Fujii, H; Konishi, M; Koshiyama, M; Tauchi, K; Yoshida, M | 1 |
| Alberts, SR; Burgart, LJ; Cera, PJ; Fishkin, PA; Goldberg, RM; Johnson, PA; Mahoney, MR; Morton, RF; Nair, S | 1 |
| Ishihara, A; Nagao, K; Tanaka, H; Toyoda, N; Umekawa, T | 1 |
| Breda, M; Britto, MR; James, CA; Jannuzzo, M; Mahteme, H; Nygren, P; Porro, M; Rocchetti, M; Sarapa, N; Speed, W; Wanders, A | 1 |
| Colucci, P; Cristofanilli, M; DeJager, R; Duggal, A; Esteva, FJ; Hortobagyi, GN; Rivera, E; Royce, M; Valero, V | 1 |
| Inoue, H; Mori, M; Ohta, M; Sadanaga, N; Tanaka, F; Yamaguchi, H | 1 |
| El-Deiry, WS; Wang, S | 1 |
| Hochster, H; Mandeli, J; Muggia, FM; Plimack, ER; Runowicz, CD; Sorich, J; Speyer, J; Wadler, S; Wallach, RC; Wright, J | 1 |
| Artale, S; Bajetta, E; Beretta, E; Biasco, G; Bonaglia, L; Bonetti, A; Buzzoni, R; Carreca, I; Cassata, A; Cortinovis, D; Di Bartolomeo, M; Ferrario, E; Frustaci, S; Iannelli, A; Lambiase, A; Mariani, L; Marini, G; Pinotti, G | 1 |
| Bafaloukos, D; Bamias, A; Economopulos, T; Fountzilas, G; Janinis, J; Kalofonos, HP; Kouvatseas, G; Papakostas, P; Skarlos, D; Stavropoulos, M; Timotheadou, E | 1 |
| Ansari, RH; Eng, C; Kasza, K; Kindler, HL; Nattam, S; Vokes, EE; Wade-Oliver, K | 1 |
| Cerman, J; Cervinka, M; Radocha, J; Rudolf, E | 1 |
| Fox, R; Melisko, ME; Venook, A | 1 |
| Sulkes, A | 1 |
| Billard, V; Bourget, P; Drouard-Troalen, L; Ducreux, M; Elias, D; Liberale, G; Matsuhisa, T; Pocard, M; Puizillou, JM; Raynard, B; Sideris, L | 1 |
| Earle, CC; Fuchs, CS; Gazelle, GS; Kwok, A | 1 |
| Hiro, J; Inoue, Y; Kobayashi, M; Kusunoki, M; Miki, C; Mori, K; Shirane, M; Tanaka, K; Yanagi, H | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hermann, R; Litchy, S; Morrissey, LH; Rodriguez, GI; Shaffer, DW; Yardley, DA | 1 |
| Cheung, YB; Chowbay, B; Leong, SS; Poon, D; Tan, EH | 1 |
| Chen, SZ; Jiang, M; Zhen, YS | 1 |
| Borsellino, N; Cartenì, G; Colucci, G; Gebbia, N; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Manzione, L; Paoletti, G; Pezzella, G; Romito, S | 1 |
| Greco, FA; Hainsworth, JD; Kommor, M; Kuzur, ME; Litchy, S; Raefsky, EL; Spigel, DR; Yost, K | 1 |
| Balasubramanian, BN; Fairchild, CR; Jang, GR; Long, B; Marathe, PH; Monticello, TM; Rose, WC; Wall, ME; Wani, MC | 1 |
| Baker, SD; Gelderblom, H; Guchelaar, HJ; Nortier, JW; Rudek, MA; Sparreboom, A; van Erp, NP; Zhao, M | 1 |
| Hladíková, J; Kubácková, K; Kubala, E; Linke, Z; Pipková, R; Prausová, J | 1 |
| Boltze, C; Fahlke, J; Hribaschek, A; Kuhn, R; Lippert, H; Meyer, F; Pross, M; Ridwelski, K | 1 |
| Barber, SE; Bekele, BN; Jasser, SA; Kim, S; Mandal, M; Myers, JN; Yazici, YD | 1 |
| Aggarwal, BB; Ajani, JA; Chao, KS; Ensor, J; Hittelman, WN; Izzo, JG; Lee, JH; Liao, Z; Luthra, R; Malhotra, U; Swisher, SG; Wu, TT | 1 |
| Chan, S; Clamp, AR; Cruickshank, D; Hindley, A; Jayson, GC; Ledermann, J; Mäenpää, J; Sorbe, B; Vasey, P; Welch, R; Wilkinson, PM | 1 |
| Bekele, BN; Jasser, SA; Kim, S; Myers, JN; Prichard, CN; Yazici, YD; Younes, MN | 1 |
| Bhonde, MR; Budczies, J; Cao, M; Daniel, PT; Gillissen, B; Hagemeier, C; Hanski, C; Hanski, ML; Mewes, HW; Moorthy, D; Scherübl, H; Simonetta, F; Truss, M; Zeitz, M | 1 |
| Abbruzzese, JL; Bogaard, K; Hoff, PM; Waldrum, S; Wolff, RA | 1 |
| Bisonni, R; Leon, A; Lippe, P; Lombardo, M; Marcucci, F; Massacesi, C; Mattioli, R; Pilone, A; Rocchi, MB; Terrazzino, S | 1 |
| Kulka, J; Pintér, T; Sipocz, I | 1 |
| Baudin, E; Boige, V; de Baere, T; Dromain, C; Ducreux, MP; Duvillard, P; Elias, D; Kergoat, P; Lasser, P; Leboulleux, S; Malka, D; Sabourin, JC; Schlumberger, M | 1 |
| Akkermans-Vogelaar, JM; Antonini, NF; de Jong, RS; Douma, J; Erdkamp, FL; Honkoop, AH; Koopman, M; Punt, CJ; Rodenburg, CJ; Vreugdenhil, G; Wals, J | 1 |
| Benson, AB; Catalano, PJ; Giantonio, BJ; Levy, DE; Meropol, NJ; O'dwyer, PJ | 1 |
| Hunter, K; Jones-Bolin, S; Klein-Szanto, A; Ruggeri, B; Zhao, H | 1 |
| Caciagli, B; Capaccioli, S; Donnini, M; Landini, I; Lapucci, A; Lulli, M; Mazzei, T; Mini, E; Morganti, M; Nobili, S; Papucci, L; Perna, F; Schiavone, N; Sobrero, A; Tempestini, A; Witort, E | 1 |
| Dedieu, S; El Btaouri, H; Ghoneim, C; Martiny, L; Morjani, H; Rath, GM; Rothhut, B; Schneider, C; Sid, B; Soula-Rothhut, M | 1 |
| Adlakha, A; Allen, JA; Bergethon, PR | 1 |
| Azarnia, N; Cohn, AL; Gold, P; Khambata-Ford, S; Lenz, HJ; Mauro, DJ; Mayer, RJ; Mirtsching, B; Pippas, AW; Rowinsky, EK; Stella, P; Tsuchihashi, Z; Van Cutsem, E | 1 |
| Andreadis, C; Gennatas, C; Michalaki, V; Mouratidou, D; Pafiti, A; Papaxoinis, G; Tsavaris, N | 1 |
| Bucana, CD; Fidler, IJ; Kitadai, Y; Kuwai, T; Nakamura, T; Sasaki, T | 1 |
| Iwazawa, T; Kanoh, T; Kimura, Y; Monden, T; Nakano, Y; Ohnishi, T; Shiozaki, K; Takemoto, H; Tono, T; Yano, H | 1 |
| Gyôrffy, B; Tegze, B; Tulassay, Z | 1 |
| Billard, V; Blot, F; Elias, D; Goere, D; Kohneh-Shahri, N; Pocard, M; Raynard, B | 1 |
| Asai, G; Fukuoka, M; Kurata, T; Nakagawa, K; Tamura, K; Uejima, H; Yamamoto, N | 1 |
| Elias, D; Goere, D; Pocard, M | 1 |
| Folprecht, G; Köhne, CH; Lutz, MP | 1 |
| Chen, LD; Li, PC; Li, Y; Zheng, F | 1 |
| Czaykowski, PM | 1 |
| Greenberger, LM; Horak, ID; Kraft, P; Longley, C; Malaby, J; Mehlig, M; Sapra, P; Zhao, H | 1 |
| Daoud, SS; Fetouh, MI; Giovanella, BC | 1 |
| Fujimori, A; Fujimori, Y; Pommier, Y; Tanizawa, A | 1 |
| Chantarawiroj, P; Edwards, CL; Freedman, RS; Gonzalez de Leon, C; Hord, M; Kavanagh, JJ; Kim, EE; Kudelka, AP; Levenback, C; Madden, T; Raber, M; Tresukosol, D; Verschraegen, C; Wallin, B | 1 |
| Dalgleish, AG; Gibson, FM; Gordon-Smith, EC; Marsh, JC; Philpott, NJ; Scopes, J; Turner, AJ; Westby, M | 1 |
| Fossella, FV; Glisson, BS; Hong, WK; Huber, MH; Kane, J; Kemp, BL; Kurie, JM; Lee, JJ; Lee, JS; Lippman, SM; Murphy, WK; Perez-Soler, R; Raber, MN; Robinson, RA; Shin, DM | 1 |
| Goldwasser, F; Hoki, Y; Jackman, J; Kohn, KW; O'Connor, PM; Pommier, Y; Shimizu, T | 1 |
| Hasuo, Y; Imaishi, K; Kataoka, A; Komai, K; Nishida, T; Ookura, N; Sugiyama, T; Ushijima, K; Yakushiji, M | 1 |
| Anderson, RC; Babel, KM; Brat, DJ; Brem, H; Ewend, MG; Pinn, ML; Tabassi, K; Tyler, BM; Williams, JA | 1 |
| Hassan, R; Kohn, E; Sandor, V | 1 |
| Clements, MK; Daoud, SS; Wasi, S | 1 |
| Chen, AY; Liu, LF | 1 |
| Armstrong, D; Carmichael, J; Gordon, A; Malfetano, J; ten Bokkel Huinink, W | 1 |
| Shimizu, Y | 1 |
| Adachi, KI; Akutsu, M; Kano, Y; Mori, K; Suzuki, K; Tsunoda, S | 1 |
| Cushman, M; Kohlhagen, G; Nagafuji, P; Paull, KD; Pommier, Y | 1 |
| Katschinski, DM; Robins, HI | 1 |
| Besmaine, A; Cuvier, C; Cvitkovic, E; Dupont-André, G; Goldwasser, F; Kalla, S; Lokiec, F; Mahjoubi, M; Marty, M; Méry-Mignard, D; Misset, JL; Ouldkaci, M; Wasserman, E | 1 |
| Hatae, M; Hiura, M; Ikeda, M; Kudoh, R; Noda, K; Ohashi, Y; Saji, F; Sato, S; Sugiyama, T; Takahashi, T; Takeuchi, S; Terashima, Y; Tomoda, Y; Umesaki, N; Yajima, A; Yakushiji, M | 1 |
| Graeven, U; Schmiegel, W | 1 |
| Hegewisch-Becker, S; Hossfeld, DK; Lipp, R; Schilling, G | 1 |
| Benedetti, F; Bertino, J; Fong, Y; Gonen, M; Jarnagin, W; Kemeny, N; Paty, P; Saltz, L; Schwartz, L; Stockman, J; Sullivan, D; Tong, W | 1 |
| Reimer, P; Rückle-Lanz, H | 1 |
| Adler, G; Lutz, MP | 1 |
| Baird, A; Burg, MA; Gonzalez, AM; Jensen-Pergakes, K; Larocca, D; Ravey, P | 1 |
| Aikawa, M; Dupree, K; Escandón, E; Fox, JA; Lowe, J; Sinicropi, D; Totpal, K; Xiang, H | 1 |
| Chauvier, D; Manfait, M; Morjani, H | 1 |
| Bristol, JA; Comins, DL; Davenport, RW; Horwitz, SB; Kane, MJ; Lyle, RE; Maloney, JR; Portlock, DE | 1 |
| Aonuma, M; Furuta, T; Kawato, Y; Matsumoto, K; Yasuoka, M; Yokokura, T | 1 |
13 review(s) available for camptothecin and Carcinoma, Anaplastic
| Article | Year |
|---|---|
The paradigm of tumor shrinkage and rapid liver remnant hypertrophy for conversion of initially unresectable colorectal liver metastasis: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Carcinoma; Colon, Sigmoid; Colonoscopy; Colorectal Neoplasms; Embolization, Therapeutic; Female; Fluorouracil; Hepatectomy; Humans; Hypertrophy; Laparoscopy; Leucovorin; Ligation; Liver; Liver Neoplasms; Liver Regeneration; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Portal Vein; Prognosis; Treatment Outcome; Vascular Surgical Procedures | 2017 |
[Current therapeutic options for liver metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Catheter Ablation; Colorectal Neoplasms; Combined Modality Therapy; Cryosurgery; Floxuridine; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Neoplasm Staging; Prognosis; Survival Rate; Time Factors | 2008 |
Irinotecan therapy and molecular targets in colorectal cancer: a systemic review.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Colorectal Neoplasms; Humans; Irinotecan; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A | 2009 |
Intermittent, repetitive administrations of irinotecan (CPT-11) reduces its side-effects.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Treatment Outcome | 2002 |
Chemotherapy in gastric cancer: a brief chronicle with emphasis on recent developments.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Docetaxel; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pyrimidines; Stomach Neoplasms; Taxoids | 2004 |
[Chemotherapy agents, response rates and mechanisms of resistance in the therapy of the colorectal carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cancer Vaccines; Carcinoma; Cetuximab; Colorectal Neoplasms; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; Fluorouracil; Humans; Hungary; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2006 |
Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Treatment Outcome | 2007 |
Design of topoisomerase inhibitors to overcome MDR1-mediated drug resistance.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma; Colonic Neoplasms; Drug Design; Drug Resistance, Neoplasm; Genes, MDR; Humans; Mice; Mice, Nude; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1994 |
Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Multicenter Studies as Topic; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Remission Induction; Safety; Survival Rate; Topoisomerase I Inhibitors; Topotecan | 1997 |
Individualized chemotherapeutic regimen for each histological subtype of ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Transitional Cell; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Mitomycin; Ovarian Neoplasms | 1997 |
[Colon carcinoma. Consensus of therapeutic strategies].
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colonic Neoplasms; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Germany; Humans; Incidence; Irinotecan; Leucovorin; Lymphatic Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prodrugs | 2000 |
[New therapeutic options in chemotherapy of advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 2001 |
[Chemotherapy of colorectal carcinoma].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Folic Acid; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Survival Analysis; Treatment Outcome | 2001 |
47 trial(s) available for camptothecin and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2017 |
A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Carcinoma; Diarrhea; Disease-Free Survival; DNA-Binding Proteins; Endometrial Neoplasms; Endonucleases; Female; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Survival Rate; Thrombocytopenia; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2018 |
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Frequency; GTP Phosphohydrolases; High-Throughput Nucleotide Sequencing; Humans; Leucovorin; Membrane Proteins; Mutation; Organoplatinum Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2015 |
Phase I Clinical Study of Irinotecan Plus S-1 in Patients With Advanced or Recurrent Cervical Cancer Previously Treated With Platinum-Based Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Drug Combinations; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur; Uterine Cervical Neoplasms | 2016 |
Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Treatment Outcome | 2008 |
Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Survival Analysis; Treatment Outcome | 2010 |
Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Salvage Therapy; Survival Analysis; Treatment Outcome | 2010 |
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Colorectal Neoplasms; Cytochrome P-450 CYP3A; Drug Dosage Calculations; Female; Humans; Individuality; Irinotecan; Male; Midazolam; Middle Aged; Models, Biological; Neoplasm Metastasis; Phenotype; Precision Medicine; Prodrugs | 2010 |
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Glutathione S-Transferase pi; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Single Nucleotide; Survival Analysis | 2010 |
EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Female; Genetic Linkage; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Salvage Therapy; Treatment Outcome | 2011 |
Unresectable peritoneal carcinomatosis from colorectal cancer: a single center experience.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Germany; Humans; Incidence; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Skin Diseases; Treatment Outcome | 2011 |
Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Disease-Free Survival; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Treatment Outcome | 2011 |
Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2011 |
CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bile Duct Neoplasms; Camptothecin; Carcinoma; Female; Gallbladder Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2002 |
Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma.
Topics: Acrylamides; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Humans; Injections, Intravenous; Male; Middle Aged; Polymers; Prodrugs | 2003 |
A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoma; Disease Progression; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival Analysis; Treatment Outcome | 2003 |
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Camptothecin; Carcinoma; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Treatment Outcome | 2004 |
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis | 2004 |
A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Survival Analysis | 2003 |
A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Disease Progression; Epothilones; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Treatment Failure | 2004 |
Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms | 2004 |
Two schedules of second-line irinotecan for metastatic colon carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Colonic Neoplasms; Cost Savings; Drug Administration Schedule; Female; Health Care Costs; Humans; Irinotecan; Male; Middle Aged; Quality of Life | 2004 |
Gene expression profiles of colorectal carcinoma in response to neo-adjuvant chemotherapy.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Interactions; Female; Floxuridine; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, fos; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Up-Regulation | 2004 |
Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Treatment Outcome | 2004 |
Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Neutropenia; Quality of Life; Salvage Therapy; Survival Analysis; Treatment Outcome | 2005 |
FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Celecoxib; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pyrazoles; Sulfonamides; Treatment Outcome | 2005 |
Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Survival Analysis; Treatment Outcome | 2005 |
Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Gene Expression Profiling; Humans; Immunohistochemistry; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; NF-kappa B; Prognosis; Taxoids; Treatment Outcome | 2006 |
SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma; Disease Progression; Docetaxel; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Indoles; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Treatment Outcome | 2006 |
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbon-Nitrogen Ligases; Carcinoma; Colorectal Neoplasms; Diarrhea; Fatigue; Female; Genotype; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neutropenia; Polymorphism, Genetic; Predictive Value of Tests; Promoter Regions, Genetic; Quinazolines; Thiophenes; Thymidylate Synthase; Vomiting | 2006 |
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Drug Administration Schedule; Enteroendocrine Cells; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Failure; Treatment Outcome | 2006 |
Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Netherlands; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2006 |
A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2006 |
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Exanthema; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Treatment Outcome | 2006 |
A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2006 |
Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Surgical; Camptothecin; Carcinoma; Female; Fluorouracil; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Postoperative Complications; Prospective Studies; Survival Rate; Topoisomerase I Inhibitors; Vitamin B Complex | 2007 |
Phase I and pharmacokinetic study of combination chemotherapy using irinotecan and paclitaxel in patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2006 |
HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Drug Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Survival Rate; Treatment Outcome | 2007 |
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan | 1996 |
Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Survival Rate; Thrombocytopenia; Topotecan; Treatment Outcome | 1996 |
[Combination of irinotecan hydrochloride (CPT-11) and cisplatin as a new regimen for patients with advanced ovarian cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms | 1996 |
Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Digestive System Neoplasms; Dose-Response Relationship, Drug; Female; Gilbert Disease; Glucuronates; Glucuronides; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Platinum; Treatment Outcome | 1999 |
Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Prospective Studies; Topoisomerase I Inhibitors; Treatment Outcome; Uterine Cervical Neoplasms | 2000 |
UFT/leucovorin plus weekly irinotecan in advanced or metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Tegafur; Uracil | 2000 |
Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma; Colonic Neoplasms; Cryosurgery; Dexamethasone; Female; Floxuridine; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Tomography, X-Ray Computed | 2001 |
102 other study(ies) available for camptothecin and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Synthesis and evaluation of mansonone F derivatives as topoisomerase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Survival; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Etoposide; Humans; Inhibitory Concentration 50; Lung Neoplasms; Naphthoquinones; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Plasmids; Pyrans; Quinones; Sesquiterpenes; Structure-Activity Relationship; Telomerase; Topoisomerase Inhibitors | 2011 |
Metastatic Parotid Gland Carcinoma With ERBB2 Amplification With Complete Response to Fam-Trastuzumab Deruxtecan.
Topics: Aged; Antibodies, Monoclonal, Humanized; Camptothecin; Carcinoma; Humans; Immunoconjugates; Male; Parotid Gland; Receptor, ErbB-2; Trastuzumab | 2022 |
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Carcinoma; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Trastuzumab; Uterine Neoplasms | 2023 |
Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Progression-Free Survival; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies | 2020 |
Conversion therapy in patients with colorectal liver metastases.
Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Logistic Models; Male; Metastasectomy; Middle Aged; Neoadjuvant Therapy; Retrospective Studies | 2021 |
Gastrin induces multidrug resistance via the degradation of p27Kip1 in the gastric carcinoma cell line SGC7901.
Topics: Aged; Camptothecin; Carcinoma; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; Gastrins; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Phosphorylation; Proteolysis; RNA, Small Interfering; S-Phase Kinase-Associated Proteins; Stomach Neoplasms | 2017 |
Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epigenesis, Genetic; ErbB Receptors; Female; Fluorouracil; Genes, ras; Humans; Leucovorin; Male; MAP Kinase Signaling System; Middle Aged; Mutation; Organoplatinum Compounds; Panitumumab; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Receptor, ErbB-2; Receptor, ErbB-3; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Wnt Signaling Pathway | 2017 |
[A Case of Triple Negative Spindle Cell Carcinoma of the Breast and Improved Quality of Life Following Irinotecan Chemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Biopsy, Needle; Camptothecin; Carcinoma; Female; Humans; Irinotecan; Middle Aged; Quality of Life; Tomography, X-Ray Computed; Triple Negative Breast Neoplasms | 2017 |
Growth inhibition of human ovarian carcinoma by a novel AvidinOX-anchored biotinylated camptothecin derivative.
Topics: Animals; Antineoplastic Agents; Avidin; Biotin; Camptothecin; Carcinoma; Cell Line, Tumor; Cell Proliferation; Female; Humans; Mice; Ovarian Neoplasms; Protein Binding | 2018 |
Nomogram predicted disease free survival for colorectal liver metastasis patients with preoperative chemotherapy followed by hepatic resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Carcinoma; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Lymph Nodes; Male; Metastasectomy; Middle Aged; Neoadjuvant Therapy; Nomograms; Organoplatinum Compounds; Oxaloacetates; Prognosis; Retrospective Studies; Survival Rate; Tumor Burden | 2019 |
Multifocal anaplastic pancreatic carcinoma requiring neoadjuvant chemotherapy and total pancreatectomy: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Treatment Outcome | 2013 |
FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Carcinoma; Cohort Studies; Drug Monitoring; Female; Fluorouracil; Gallbladder Neoplasms; Humans; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Secondary Prevention; Severity of Illness Index; Survival Analysis | 2013 |
Durable response after just one cycle of belotecan-based chemotherapy in a patient with relapsed primary peritoneal serous carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Female; Humans; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Peritoneum; Topoisomerase I Inhibitors; Treatment Outcome | 2014 |
Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.
Topics: Abdominal Abscess; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cytoreduction Surgical Procedures; Digestive System Fistula; Female; Fluorouracil; Hematoma; Humans; Hyperthermia, Induced; Length of Stay; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Peritoneal Neoplasms; Wound Healing | 2014 |
Correlation between the methylation of SULF2 and WRN promoter and the irinotecan chemosensitivity in gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Carcinoma, Signet Ring Cell; DNA Methylation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Exodeoxyribonucleases; Female; Humans; Irinotecan; Male; Middle Aged; Prognosis; Promoter Regions, Genetic; RecQ Helicases; Stomach Neoplasms; Sulfatases; Sulfotransferases; Werner Syndrome Helicase | 2013 |
Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Cohort Studies; Colorectal Neoplasms; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Irinotecan; Male; Mesothelioma; Middle Aged; Mitomycin; Neoplasms, Multiple Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Peritoneum; Prospective Studies; Pseudomyxoma Peritonei; Quality of Life; Stomach Neoplasms; Treatment Outcome | 2014 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Blood Transfusion; Camptothecin; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Gallbladder Neoplasms; Humans; Hyperthermia, Induced; Intraoperative Care; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Pseudomyxoma Peritonei; Stomach Neoplasms; Survival Rate; Tertiary Care Centers | 2014 |
Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2014 |
Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cohort Studies; Colorectal Neoplasms; Disease-Free Survival; Duodenal Neoplasms; Female; Humans; Hyperthermia, Induced; Ileal Neoplasms; Infusions, Parenteral; Intestine, Small; Irinotecan; Jejunal Neoplasms; Male; Metastasectomy; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Peritoneal Lavage; Peritoneal Neoplasms; Peritoneum; Retrospective Studies; Treatment Outcome | 2014 |
Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma; Colonic Neoplasms; Female; HT29 Cells; Humans; Irinotecan; Liposomes; Mice; Mice, Inbred NOD; Mice, SCID; Prodrugs; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the Anatolian Society of Medical Oncology.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptothecin; Capecitabine; Carcinoma; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates; Retrospective Studies; Treatment Outcome | 2014 |
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Carcinoma; Colorectal Neoplasms; Disease-Free Survival; DNA; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Prospective Studies | 2015 |
Ampulla of Vater carcinoma in real-world clinical practice: a case series.
Topics: Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organ Sparing Treatments; Organoplatinum Compounds; Pancreaticoduodenectomy; Pylorus; Retrospective Studies; Treatment Outcome | 2015 |
Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Mice; Molecular Structure; Nanoparticles; Neoplasms, Experimental; Organoplatinum Compounds; Oxaliplatin; Prodrugs; RNA Interference | 2016 |
Unusual case of hyperpigmentation secondary to irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; Drug Eruptions; Female; Humans; Hyperpigmentation; Irinotecan; Middle Aged; Mouth Mucosa; Nails; Neoplasm Recurrence, Local | 2016 |
Granulocyte Colony-stimulating Factor Producing Anaplastic Carcinoma of the Pancreas: Case Report and Review of the Literature.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leukocyte Count; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Receptors, Granulocyte Colony-Stimulating Factor; Tomography Scanners, X-Ray Computed | 2017 |
Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Retrospective Studies; Survival Rate | 2009 |
TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genotype; HSP90 Heat-Shock Proteins; HT29 Cells; Humans; Irinotecan; Male; Middle Aged; Mitochondria; Organoplatinum Compounds; Oxaliplatin; Peptide Fragments; Phenotype; RNA, Messenger; Transfection; Up-Regulation | 2009 |
Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy.
Topics: Animals; Anti-Infective Agents; Antibiotic Prophylaxis; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Ciprofloxacin; Colorectal Neoplasms; Diarrhea; Female; Immunity, Mucosal; Intestinal Mucosa; Irinotecan; Lymphatic Metastasis; Neoplasm Transplantation; Rats; Rats, Inbred F344; Spleen; Survival Analysis | 2009 |
[Cetuximab and irinotecan for the treatment of metastatic colorectal cancer--pilot results from Masaryk Memorial Cancer Institute].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Survival Rate | 2009 |
Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; DNA Mutational Analysis; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Organoplatinum Compounds; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Treatment Outcome | 2009 |
Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: a pilot study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Pilot Projects; Sirolimus; Treatment Outcome | 2009 |
[Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC): evaluation, prevention and policies to avoid occupational exposure for operating room personnel].
Topics: Air Pollutants, Occupational; Antineoplastic Agents; Camptothecin; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Decontamination; Doxorubicin; Drug Compounding; Electrosurgery; Hot Temperature; Humans; Irinotecan; Mitomycin; Occupational Exposure; Operating Rooms; Organoplatinum Compounds; Peritoneal Neoplasms; Protective Clothing; Pyridines; Smoke; Ventilation | 2009 |
CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Carcinoembryonic Antigen; Carcinoma; Colonic Neoplasms; Drug Delivery Systems; Female; GPI-Linked Proteins; Humans; Immunoconjugates; Irinotecan; Mice; Mice, Nude; Models, Biological; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Irinotecan and mismatch repair deficiency.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Camptothecin; Carcinoma; Colorectal Neoplasms; DNA Mismatch Repair; DNA Repair-Deficiency Disorders; Drug Resistance, Neoplasm; Humans; Irinotecan; Liver Neoplasms; Postoperative Period; Prognosis | 2010 |
Novel tumor-targeted RGD peptide-camptothecin conjugates: synthesis and biological evaluation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Female; Humans; Mice; Mice, Nude; Molecular Structure; Oligopeptides; Ovarian Neoplasms | 2010 |
Downregulation of ANP32B, a novel substrate of caspase-3, enhances caspase-3 activation and apoptosis induction in myeloid leukemic cells.
Topics: Acetophenones; Antineoplastic Agents; Apoptosis; Benzopyrans; Camptothecin; Carcinoma; Caspase 3; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Down-Regulation; Enzyme Activation; Female; Humans; Leukemia, Myeloid; Male; Neoplasm Proteins; Neoplasms; Nuclear Proteins; Recombinant Fusion Proteins; RNA Interference; RNA, Small Interfering; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Substrate Specificity | 2010 |
Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Epithelium; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Survival Analysis; Topotecan | 2010 |
Pharmacokinetics of intraperitoneal irinotecan in a pig model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Camptothecin; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; Dose-Response Relationship, Drug; Female; Irinotecan; Peritoneal Neoplasms; Swine | 2010 |
Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study.
Topics: Adult; Aged; Alabama; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Catheter Ablation; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Chi-Square Distribution; Colorectal Neoplasms; Czech Republic; Female; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Kentucky; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Proportional Hazards Models; Prospective Studies; Registries; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
p53 downregulates the gene expression of mitochondrial aconitase in human prostate carcinoma cells.
Topics: Aconitate Hydratase; Camptothecin; Carcinoma; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Male; Mitochondria; Mutation; Prostatic Neoplasms; Response Elements; Thiazoles; Tumor Suppressor Protein p53 | 2011 |
Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colonic Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; HCT116 Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; Mice; Mice, Nude; Models, Biological; Naphthalenes; Organoplatinum Compounds; Oxaliplatin; Xenograft Model Antitumor Assays | 2010 |
Pancreatic metastasis from colon carcinoma treated with radiotherapy with palliative benefit.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Pain; Palliative Care; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Treatment Outcome | 2010 |
Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Camptothecin; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Organoplatinum Compounds; Professional Practice; Standard of Care; Treatment Outcome; Young Adult | 2011 |
Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Germany; Health Status Indicators; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Peritoneal Neoplasms; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Survival Rate; Time Factors; Treatment Outcome | 2010 |
[A case of spindle cell carcinoma of the breast, in which irinotecan was effective against respiratory failure due to pulmonary metastases].
Topics: Antineoplastic Agents, Phytogenic; Biopsy, Needle; Breast Neoplasms; Camptothecin; Carcinoma; Fatal Outcome; Female; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Respiratory Insufficiency; Tomography, X-Ray Computed | 2011 |
Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Fluorouracil; Humans; Japan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Retrospective Studies | 2011 |
CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis.
Topics: Abdominal Wall; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Carriers; Drug Delivery Systems; Drug Evaluation, Preclinical; Humans; Hyaluronan Receptors; Hyaluronic Acid; Inhibitory Concentration 50; Injections, Intraperitoneal; Irinotecan; Male; Neoplasm Transplantation; Peritoneal Neoplasms; Random Allocation; Rats; Rats, Inbred Strains | 2011 |
Second-line chemotherapy in patients with primary unknown cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Failure; Treatment Outcome | 2011 |
Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Diagnosis, Differential; Disease Progression; Feasibility Studies; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Survival Analysis; Thymus Neoplasms; Treatment Outcome | 2011 |
Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Cell Line, Tumor; Colonic Neoplasms; Drug Evaluation, Preclinical; Gene Expression Regulation, Neoplastic; HCT116 Cells; Hep G2 Cells; Humans; Inactivation, Metabolic; Irinotecan; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Signal Transduction; Up-Regulation; Xenobiotics | 2011 |
Salvage chemotherapy for ovarian carcinoma recurring during or after consolidation chemotherapy with paclitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Disease-Free Survival; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Salvage Therapy; Time Factors; Treatment Outcome | 2011 |
Treatment results of peritonectomy combined with perioperative chemotherapy for colorectal cancer-patients with peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Pelvic Exenteration; Peritoneal Neoplasms; Young Adult | 2011 |
Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chi-Square Distribution; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Proportional Hazards Models; Retrospective Studies; Tomography, X-Ray Computed; Ultrasonography | 2012 |
EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Fluorouracil; Genotype; Humans; Leucovorin; Middle Aged; Polycomb Repressive Complex 2; Polymorphism, Single Nucleotide; Prognosis; Risk Assessment; Survival Analysis; Transcription Factors | 2012 |
Combined portal vein embolization and preoperative chemotherapy prior to liver resection for colorectal cancer metastases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Blood Loss, Surgical; Blood Volume; Camptothecin; Carcinoma; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Embolization, Therapeutic; Female; Hepatectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Length of Stay; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Operative Time; Organoplatinum Compounds; Oxaliplatin; Portal Vein; Retrospective Studies; Statistics, Nonparametric | 2012 |
Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Products; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Cohort Studies; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Hyperthermia, Induced; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Peritoneal Neoplasms; Retrospective Studies; Treatment Outcome; United States | 2013 |
Irinotecan induces senescence and apoptosis in colonic cells in vitro.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma; Cellular Senescence; Colon; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; DNA Damage; Fibroblasts; Gene Expression Regulation; Gene Knockdown Techniques; HCT116 Cells; Humans; Irinotecan; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Signal Transduction; Tumor Suppressor Protein p53 | 2012 |
The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Camptothecin; Carcinoma; Caspase 9; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Topics: Acid Anhydride Hydrolases; Antineoplastic Agents; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Protein; Camptothecin; Carcinoma; Cell Cycle Proteins; Cell Line, Tumor; DNA Damage; DNA Repair Enzymes; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gamma Rays; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Intracellular Signaling Peptides and Proteins; Male; MRE11 Homologue Protein; Neoplasms; Nuclear Proteins; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Recombinational DNA Repair; Tumor Suppressor p53-Binding Protein 1 | 2012 |
Clinical outcome of up-front surgery in patients with asymptomatic, incurable synchronous peritoneal carcinomatosis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Humans; Intestinal Obstruction; Irinotecan; Male; Middle Aged; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Postoperative Complications; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
Chemosensitivity in ovarian metastases from gastric cancer: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Female; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Ovariectomy; Stomach Neoplasms | 2013 |
Influence of G2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma; Cell Cycle; Colonic Neoplasms; Etoposide; Humans; Staurosporine; Topoisomerase Inhibitors; Tumor Suppressor Protein p53 | 2002 |
Prevention and treatment of peritoneal carcinomatosis in experimental investigations with CPT-11 and oxaliplatin.
Topics: Anesthesia; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Injections, Intraperitoneal; Irinotecan; Male; Neoplasm Recurrence, Local; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Rats; Tumor Cells, Cultured | 2002 |
Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in platinum- and paclitaxel-resistant epithelial ovarian cancer: case reports.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Mitomycin; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Salvage Therapy; Sampling Studies; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Stimulation of CD40 inhibits Fas- or chemotherapy-mediated apoptosis and increases cell motility in human gastric carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma; CD40 Antigens; CD40 Ligand; Cell Division; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Survival; fas Receptor; Flow Cytometry; Humans; Stomach Neoplasms; Tetrazolium Salts; Thiazoles | 2003 |
Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Base Pair Mismatch; bcl-2-Associated X Protein; Camptothecin; Carcinoma; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Cell Death; Cell Line; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA Repair; Enzyme Inhibitors; Etoposide; Flow Cytometry; Humans; Irinotecan; Luciferases; Membrane Glycoproteins; Mice; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; RNA, Small Interfering; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic; Transfection; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53 | 2003 |
Combined effect of sodium selenite and campthotecin on cervical carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma; Caspase 3; Caspases; Cell Division; Cell Line, Tumor; Cell Nucleus; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Activation; Female; HeLa Cells; Humans; Mitochondria; Oxidative Stress; Sodium Selenite; Time Factors; Uterine Cervical Neoplasms | 2004 |
Reactivation of hepatitis C virus after chemotherapy for colon cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colonic Neoplasms; Fluorouracil; Hepatitis C; Humans; Immunocompromised Host; Irinotecan; Leucovorin; Male; Recurrence | 2004 |
HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Biomarkers; Breast Neoplasms; Camptothecin; Carcinoma; Colonic Neoplasms; Coloring Agents; Drug Interactions; Drug Resistance, Neoplasm; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Gene Expression Profiling; Humans; Lung Neoplasms; Paclitaxel; Potassium Channels, Voltage-Gated; Tetrazolium Salts; Thiazoles; Transfection; Vincristine | 2005 |
Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Female; Gastrointestinal Tract; Humans; Irinotecan; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, Nude; Ovarian Neoplasms; Prodrugs; Rats; Rats, Sprague-Dawley; Tumor Burden; Xenograft Model Antitumor Assays | 2006 |
Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Carcinoma; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Synergism; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Plant Extracts; Silybum marianum; Time Factors | 2005 |
[Irinotecan in combination with 5-fluorouracil and leucovorin in the treatment of metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged | 2005 |
Intraperitoneal versus intravenous CPT-11 given intra- and postoperatively for peritoneal carcinomatosis in a rat model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Enzyme Inhibitors; Infusions, Parenteral; Irinotecan; Male; Models, Animal; Neoplasm Transplantation; Neoplasms, Experimental; Peritoneal Neoplasms; Postoperative Period; Rats | 2006 |
Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and CPT-11.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Phthalazines; Protein Kinase Inhibitors; Pyridines; Thyroid Neoplasms | 2006 |
Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma; Cell Adhesion; Cell Proliferation; Cetuximab; Drug Interactions; Drug Synergism; Humans; Irinotecan; Lymphatic Metastasis; Male; Mice; Mice, Nude; Survival Rate; Thyroid Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 2006 |
DNA damage-induced expression of p53 suppresses mitotic checkpoint kinase hMps1: the lack of this suppression in p53MUT cells contributes to apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Carcinoma; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; Flow Cytometry; Gene Expression Regulation, Neoplastic; HCT116 Cells; HeLa Cells; HT29 Cells; Humans; Irinotecan; Models, Biological; Neoplasm Proteins; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Suppressor Protein p53 | 2006 |
[The results of cetuximab treatment of a patient with multiple pretreated, irinotecan resistant metastatic colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Signal Transduction; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbazoles; Carcinoma; Colonic Neoplasms; Dacarbazine; Glioblastoma; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Temozolomide; Xenograft Model Antitumor Assays | 2006 |
Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Oligonucleotide Array Sequence Analysis; Poly A; RNA, Messenger | 2005 |
The C-terminal CD47/IAP-binding domain of thrombospondin-1 prevents camptothecin- and doxorubicin-induced apoptosis in human thyroid carcinoma cells.
Topics: Apoptosis; Binding Sites; Camptothecin; Carcinoma; CD47 Antigen; Cell Differentiation; Cell Line, Tumor; Doxorubicin; Humans; Thrombospondin 1; Thyroid Neoplasms; Time Factors; Transfection | 2006 |
Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aphasia; Bevacizumab; Blindness, Cortical; Blood Vessels; Camptothecin; Carcinoma; Cognition Disorders; Colonic Neoplasms; Dementia, Vascular; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Occipital Lobe; Parietal Lobe; Vascular Endothelial Growth Factor A | 2006 |
Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Camptothecin; Carcinoma; Cecum; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Synergism; Humans; Imatinib Mesylate; Irinotecan; Liver; Male; Mice; Mice, Nude; Pericytes; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Stromal Cells; Transplantation, Heterologous | 2006 |
[A case of successfully treated unresectable multiple liver metastases from colon cancer by hepatic arterial infusion chemotherapy and systemic chemotherapy].
Topics: Aged; Camptothecin; Carcinoma; Colectomy; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Remission Induction; Sigmoid Neoplasms | 2006 |
Intraperitoneal chemotherapy with hydroxycamptothecin reduces peritoneal carcinomatosis: results of an experimental study.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Humans; Injections, Intraperitoneal; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Peritoneal Neoplasms; Survival Rate; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2008 |
Therapy of colon carcinoma: an oncology perspective. Interview with Piotr M. Czaykowski by Paul C. Adams.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Carcinoma; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Quinazolines; Rectal Neoplasms; Thiophenes | 2007 |
Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Carcinoma; Cell Proliferation; Colorectal Neoplasms; Disease Models, Animal; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Mice; Mice, Nude; Models, Biological; Neoplasms; Pancreatic Neoplasms; Polyethylene Glycols; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Animals; Breast Neoplasms; Camptothecin; Carcinoma; Cholesterol; Drug Carriers; Drug Evaluation, Preclinical; Humans; Liposomes; Melanoma, Experimental; Mice; Mice, Nude; Molecular Structure; Neoplasm Proteins; Neoplasm Transplantation; Phosphatidylinositols; Remission Induction; Skin Neoplasms; Sphingomyelins; Topoisomerase I Inhibitors | 1995 |
Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.
Topics: Camptothecin; Carcinoma; Clinical Trials as Topic; Colonic Neoplasms; DNA, Neoplasm; Humans; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1994 |
The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques.
Topics: Apoptosis; Camptothecin; Carcinoma; Cell Count; Cell Separation; Dactinomycin; DNA Damage; DNA, Neoplasm; Flow Cytometry; Fluorescent Dyes; Humans; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Erythroblastic, Acute; Pancreatic Neoplasms; Reproducibility of Results; Sensitivity and Specificity; Tumor Cells, Cultured | 1996 |
Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Aphidicolin; Camptothecin; Carcinoma; CDC2 Protein Kinase; Colonic Neoplasms; Cyclins; DNA Damage; DNA Repair; DNA Replication; Enzyme Inhibitors; G2 Phase; Humans; S Phase; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1996 |
Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Camptothecin; Carboplatin; Carcinoma; Carcinoma, Lewis Lung; Carmustine; Colonic Neoplasms; Combined Modality Therapy; Female; Humans; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Transplantation; Polymers; Radiotherapy Dosage; Tumor Cells, Cultured | 1996 |
Exacerbation of pseudogout by granulocyte colony-stimulating factor.
Topics: Aged; Antineoplastic Agents; Camptothecin; Carcinoma; Chondrocalcinosis; Combined Modality Therapy; Female; Granulocyte Colony-Stimulating Factor; Humans; Ovarian Neoplasms; Recombinant Proteins; Recurrence | 1996 |
Camptothecin exhibits selective cytotoxicity towards human breast carcinoma as compared to normal bovine endothelial cells in vitro.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; Camptothecin; Carcinoma; Cattle; Cell Division; Cell Nucleus; Cells, Cultured; DNA Topoisomerases, Type I; Endothelium, Vascular; Humans; Liposomes; Mice; Tumor Cells, Cultured | 1996 |
In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cell Division; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Irinotecan; Paclitaxel; Tumor Cells, Cultured | 1998 |
Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoma; DNA Damage; DNA, Neoplasm; Drug Screening Assays, Antitumor; Humans; Indenes; Isoquinolines; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1998 |
Hyperthermic modulation of SN-38-induced topoisomerase I DNA cross-linking and SN-38 cytotoxicity through altered topoisomerase I activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Cell Division; Cell Nucleus; Cell Survival; DNA Topoisomerases, Type I; DNA, Neoplasm; Dose-Response Relationship, Drug; Fibrosarcoma; Hot Temperature; Humans; Hyperthermia, Induced; Irinotecan; Kinetics; Lung Neoplasms; Mice; Topoisomerase I Inhibitors | 1999 |
Enhanced phagemid particle gene transfer in camptothecin-treated carcinoma cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacteriophages; Camptothecin; Carcinoma; Combined Modality Therapy; Enzyme Inhibitors; Epidermal Growth Factor; Genetic Therapy; Genetic Vectors; Humans; Male; Mice; Mice, Nude; Neoplasms; Plasmids; Transduction, Genetic; Transfection; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Carcinoma; Caspases; Cell Cycle; Cells, Cultured; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Synergism; Humans; Irinotecan; Kinetics; Membrane Glycoproteins; Neoplasms; Receptors, Tumor Necrosis Factor; RNA, Neoplasm; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
Homocamptothecin-daunorubicin association overcomes multidrug-resistance in breast cancer MCF7 cells.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma; Colonic Neoplasms; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Leukemia, Myeloid; Microbial Sensitivity Tests; Multidrug Resistance-Associated Proteins; Polymerase Chain Reaction; RNA, Neoplasm; Treatment Outcome; Tumor Cells, Cultured | 2002 |
Analogs of camptothecin.
Topics: Animals; Camptothecin; Carcinoma; Cell Line; Leukemia L1210; Mouth Neoplasms | 1975 |
Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Injections, Intravenous; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous | 1991 |